[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598008":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":70,"collaborators":73,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University of Alberta","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Aneurysmal subarachnoid hemorrhage (SAH) Patients",null,"Adult patients admitted for aneurysmal SAH to any of the participating centres, who consent to participate in the study and meet the inclusion and exclusion criteria.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Sherif H Mahmoud, BSc (Pharm), MSc, PhD, FNCS","CONTACT","780.492.5364","smahmoud@ualberta.ca",[19,38,55],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"VCU Medical Center","RECRUITING","Richmond","Virginia","23219","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-77.46026,37.55376,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":36,"phoneExt":10,"email":37},"Gretchen M Brophy, PharmD, BCPS, FCCP, FNCS, MCCM","804-828-1201","gbrophy@vcu.edu",{"facility":39,"status":21,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"University of Alberta Hospital","Edmonton","Alberta","T6G 2X8","Canada","CA",{"type":28,"coordinates":46},[47,48],-113.46871,53.55014,{"lat":48,"lon":47},[51,53],{"name":14,"role":15,"phone":52,"phoneExt":10,"email":17},"780-492-5364",{"name":14,"role":54,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":21,"city":57,"state":58,"zip":59,"country":43,"countryCode":44,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"University Health Network - Toronto Western Hospital","Toronto","Ontario","M5T 2S8",{"type":28,"coordinates":61},[62,63],-79.39864,43.70643,{"lat":63,"lon":62},[66],{"name":67,"role":15,"phone":68,"phoneExt":10,"email":69},"Victoria McCredie, MBChB PhD FRCP(C) FRCP(UK)","416-302-1959","Victoria.McCredie@uhn.ca",{"type":54,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sherif Mahmoud","Associate Professor",[74,77,79,81,83,85],{"name":75,"class":76},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV",{"name":78,"class":6},"Alberta Health services",{"name":80,"class":6},"Foothills Medical Centre",{"name":82,"class":6},"Montreal Neurological Institute and Hospital",{"name":84,"class":6},"University Health Network, Toronto",{"name":86,"class":6},"Virginia Commonwealth University","100598008","nimodipine-variability-in-sah-100598008",false,"NCT07065903","Nimodipine Variability in SAH","Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)","ASH-II","Inclusion Criteria:\n\n* Age 18-85 years\n* Diagnosis of aneurysmal SAH\n* Provision of informed consent\n* Treated with nimodipine\n* Presence of intravascular catheter at the time of sampling\n\nExclusion Criteria:\n\n* Anticipated hospital length of stay \\\u003C48 hours\n* Non-aneurysmal SAH\n* Not treated with nimodipine\n* Incarceration\n* Delayed presentation to the hospital (\\>96 h from SAH onset)","ALL","18 Years","85 Years",{"count":99,"type":100},500,"ESTIMATED","OBSERVATIONAL","Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patients during their most productive years. Complications following SAH are common, and they can cause major long-term disability. Only one medication - nimodipine - has been proven to benefit the health and wellbeing of these patients. All SAH patients should receive nimodipine for 21 days at a fixed dose. However, our early work suggested that all patients are not getting equal amounts of nimodipine into their blood. In addition, the two different forms (structural mirror images) of nimodipine might have different effects. Reduced amounts of nimodipine in the blood may lessen its benefit and contribute to worsening health and wellbeing of SAH patients.\n\nThe overall goal of this research is to see what happens with different nimodipine doses and to confirm whether the two forms of nimodipine have different effects. The investigators will conduct a multi-centre study in adult patients admitted for SAH in Canada and the USA. The investigators will collect blood samples to determine the amount of each type of nimodipine in each participant's body, and then will check to see how each participant is doing at 90 days following SAH. They will also check other factors affecting nimodipine levels, so that they can in the future suggest dose recommendations that are actually tailored to each patient.",[104,105],"Subarachnoid Aneurysm Hemorrhage","Subarachnoid Hemorrhage, Aneurysmal",[107,108,109],"nimodipine","subarachnoid hemorrhage","pharmacokinetics","2026-02-04",{"date":112,"type":113},"2026-02-09","ACTUAL",{"date":115,"type":113},"2024-05-13",{"date":117,"type":100},"2029-09",{"name":5,"class":6},3]